摘要
目的探讨肥胖或超重血糖控制不佳2型糖尿病患者胰岛素联合恩格列净治疗的疗效和安全性。方法回顾性选取2019年6月—2020年6月该院内分泌科血糖控制不佳肥胖或超重2型糖尿病患者100例,依据治疗方法分为胰岛素联合恩格列净治疗组(联合治疗组,n=50)、胰岛素单独治疗组(单独治疗组,n=50)两组,统计分析两组患者的体质指数、血糖水平、胰岛素用量、血糖达标时间、不良反应发生情况。结果联合治疗组患者治疗后较治疗前的体质指数、糖化血红蛋白、餐后2 h血糖、空腹血糖降低幅度均显著高于单独治疗组,差异有统计学意义(P<0.05)。联合治疗组患者的胰岛素用量显著少于单独治疗组,差异有统计学意义(t=7.210,P<0.05),血糖达标时间显著短于单独治疗组,差异有统计学意义(t=10.689,P<0.05)。在不良反应发生率方面,联合治疗组为6.0%(3/50),单独治疗组为8.0%(4/50),差异无统计学意义(χ^(2)=0.000,P>0.05)。结论肥胖或超重血糖控制不佳2型糖尿病患者胰岛素联合恩格列净治疗的疗效较胰岛素单独治疗显著,且安全性有保证。
Objective To investigate the efficacy and safety of insulin combined with empagliflozin in the treatment of obese or overweight patients with poor blood sugar control in type 2 diabetes.Methods A retrospective selection of 100 patients with obesity or overweight type 2 diabetes with poor blood glucose control in the department of endocrinology of the hospital from June 2019 to June 2020 were divided into insulin combined with empagliflozin treatment group(combined treatment group,n=50),insulin alone treatment group(single treatment group,n=50)two groups,statistical analysis of the body mass index,blood glucose level,insulin dosage,blood glucose reaching standard time,and adverse reactions of the two groups of patients.Results The reduction of body mass index,glycosylated hemoglobin,2 h postprandial blood glucose and fasting blood glucose of patients in the combined treatment group were significantly higher than those in the single treatment group after treatment,and the difference was statistically significant(P<0.05).The insulin dosage of the combined treatment group was significantly less than that of the single treatment group,and the difference was statistically significant(t=7.210,P<0.05),and the blood glucose reaching target time was significantly shorter than that of the single treatment group,and the difference was statistically significant(t=10.689,P<0.05).In terms of the incidence of adverse reactions,the combined treatment group was 6.0%(3/50)and the single treatment group was 8.0%(4/50).The difference between the two groups was not statistically significant(χ^(2)=0.000,P>0.05).Conclusion The efficacy of insulin combined with empagliflozin in obese or overweight patients with poor blood glucose control is more significant than that of insulin alone,and the safety is guaranteed.
作者
赵海桃
ZHAO Haitao(Department of Endocrinology,Jiangmen People's Hospital,Jiangmen,Guangdong Province,529020 China)
出处
《系统医学》
2021年第14期60-62,119,共4页
Systems Medicine
关键词
肥胖或超重
血糖控制不佳
2型糖尿病
胰岛素
恩格列净
疗效
安全性
Obesity or overweight
Poor blood glucose control
Type 2 diabetes
Insulin
Empagliflozin
Efficacy
Safety
作者简介
赵海桃(1984-),女,本科,主治医师,研究方向为糖尿病及并发症,甲状腺疾病等内分泌代谢方面。
